Professor Rhonda Rosengren
| Position | Professor |
|---|---|
| Department | Department of Pharmacology and Toxicology |
| Qualifications | BS PhD(Texas A & M) |
| Research summary | Breast and prostate cancer, nanomedicine, drug metabolism |
| Memberships | Professor Rhonda Rosengren is a member of the Auckland Cancer Research Network |
Research
Toxicological research in my laboratory involves the identification of novel treatments for various cancers including estrogen receptor negative breast cancer, hormone refractory prostate cancer and ovarian cancer. In conjunction with Dr. Bill Hawkins in the department of Chemistry we are synthesizing novel curcumin derivatives and examining their activity in both in vitro and in vivo models of cancer. We have also discovered new roles for tamoxifen and raloxifene in breast and prostate cancer when given as part of a novel combination therapy or in novel formulations. We also have research collaborations with Dr. Andrew Cridge in the Department of Biochemistry, Dr. Jonathan Bray Head of Small Animal Surgery at Massey University Veterinary School, Dr. Heather Cunliffe in the Department of Pathology and Dr. Mihnea Bostina in the Department of Microbiology and Immunology. The Otago Medical Research Foundation and grants from the University of Otago currently fund our work.
Additional details
- Professor Rhonda Rosengren's research group
- Professor Rhonda Rosengren's contact details
- Professor Rhonda Rosengren's publications on ResearchGate
In the news
- Breast cancer breakthrough (New Zealand Herald)
- Cancer research funding (Otago Daily Times)
- $300K made available to support innovative breast cancer research in NZ (New Zealand Breast Cancer Foundation)
- New projects take NZBCF research spend to $800,000 over the next two years (New Zealand Doctor)
- Research targets better drug treatment for breast cancers (Scoop)
- University promotes academics (Otago Daily Times)
- Otago announces professorial promotions (Scoop)
Publications
Hanif, M., Arshad, J., Astin, J. W., Rana, Z., Zafari, A., Movassaghi, S., … Rosengren, R. J., … Hartinger, C. G. (2020). A multitargeted approach: Organorhodium anticancer agent based on vorinostat as a potent histone deacetylase inhibitor. Angewandte Chemie International Edition, 59, 14609-14614. doi: 10.1002/anie.202005758
Shrestha, N., Bland, A. R., Bower, R. L., Rosengren, R. J., & Ashton, J. C. (2020). Inhibition of mitogen-activated protein kinase kinase alone and in combination with anaplastic lymphoma kinase (ALK) inhibition suppresses tumor growth in a mouse model of ALK-positive lung cancer. Journal of Pharmacology & Experimental Therapeutics, 374, 134-140. doi: 10.1124/jpet.120.266049
Rana, Z., Diermeier, S., Hanif, M., & Rosengren, R. J. (2020). Understanding failure and improving treatment using HDAC inhibitors for prostate cancer. Biomedicines, 8(2), 22. doi: 10.3390/biomedicines8020022
Bland, A. R., Shrestha, N., Rosengren, R. J., & Ashton, J. C. (2020). Does crizotinib auto-inhibit CYP3A in vivo? [Brief report]. Pharmacology. Advance online publication. doi: 10.1159/000506996
Singh, R. J., Martin, C. E., Barr, D., & Rosengren, R. J. (2019). Cucumber peel bead biosorbent for multi-ion decontamination of drinking water collected from a mine region in New Zealand. Environmental Technology. Advance online publication. doi: 10.1080/09593330.2019.1703824
Journal - Research Article
Shrestha, N., Bland, A. R., Bower, R. L., Rosengren, R. J., & Ashton, J. C. (2020). Inhibition of mitogen-activated protein kinase kinase alone and in combination with anaplastic lymphoma kinase (ALK) inhibition suppresses tumor growth in a mouse model of ALK-positive lung cancer. Journal of Pharmacology & Experimental Therapeutics, 374, 134-140. doi: 10.1124/jpet.120.266049
Hanif, M., Arshad, J., Astin, J. W., Rana, Z., Zafari, A., Movassaghi, S., … Rosengren, R. J., … Hartinger, C. G. (2020). A multitargeted approach: Organorhodium anticancer agent based on vorinostat as a potent histone deacetylase inhibitor. Angewandte Chemie International Edition, 59, 14609-14614. doi: 10.1002/anie.202005758
Smith, R. J., Bower, R. L., Ferguson, S. A., Rosengren, R. J., Cook, G. M., & Hawkins, B. C. (2019). The synthesis of (±)-oxyisocyclointegrin. European Journal of Organic Chemistry, (7), 1571-1573. doi: 10.1002/ejoc.201801751
Bland, A. R., Bower, R. L., Nimick, M., Hawkins, B. C., Rosengren, R. J., & Ashton, J. C. (2019). Cytotoxicity of curcumin derivatives in ALK positive non-small cell lung cancer. European Journal of Pharmacology, 865, 172749. doi: 10.1016/j.ejphar.2019.172749
Singh, R. J., Martin, C. E., Barr, D., & Rosengren, R. J. (2019). Cucumber peel bead biosorbent for multi-ion decontamination of drinking water collected from a mine region in New Zealand. Environmental Technology. Advance online publication. doi: 10.1080/09593330.2019.1703824
Martey, O. N. K., Greish, K., Smith, P. F., & Rosengren, R. J. (2019). A multivariate statistical analysis of the effects of styrene maleic acid encapsulated RL71 in a xenograft model of triple negative breast cancer. Journal of Biological Methods, 6(4). doi: 10.14440/jbm.2019.306
Shrestha, N., Nimick, M., Dass, P., Rosengren, R. J., & Ashton, J. C. (2019). Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer. Scientific Reports, 9, 18842. doi: 10.1038/s41598-019-55376-4
Shrestha, N., Lateef, Z., Martey, O., Bland, A. R., Nimick, M., Rosengren, R., & Ashton, J. C. (2019). Does the mouse tail vein injection method provide a good model of lung cancer? F1000Research, 8, 190. doi: 10.12688/f1000research.17964.1
Chen, S., Nimick, M., Cridge, A. G., Hawkins, B. C., & Rosengren, R. J. (2018). Anticancer potential of novel curcumin analogs towards castrate-resistant prostate cancer. International Journal of Oncology, 52(2), 579-588. doi: 10.3892/ijo.2017.4207
Megna, B. W., Carney, P. R., Depke, M. G., Nukaya, M., McNally, J., Larsen, L., Rosengren, R. J., & Kennedy, G. D. (2017). The aryl hydrocarbon receptor as an antitumor target of synthetic curcuminoids in colorectal cancer. Journal of Surgical Research, 213, 16-24. doi: 10.1016/j.jss.2017.02.010
Martey, O., Nimick, M., Taurin, S., Sundararajan, V., Greish, K., & Rosengren, R. J. (2017). Styrene maleic acid-encapsulated RL71 micelles suppress tumor growth in a murine xenograft model of triple negative breast cancer. International Journal of Nanomedicine, 12, 7225-7237. doi: 10.2147/ijn.s148908
Revalde, J. L., Li, Y., Wijeratne, T. S., Budge, P., Hawkins, B. C., Rosengren, R. J., & Paxton, J. W. (2017). Curcumin and its cyclohexanone analogue inhibited human Equilibrative nucleoside transporter 1 (ENT1) in pancreatic cancer cells. European Journal of Pharmacology, 803, 167-173. doi: 10.1016/j.ejphar.2017.03.055
Archibald, M., Pritchard, T., Nehoff, H., Rosengren, R. J., Greish, K., & Taurin, S. (2016). A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer. International Journal of Nanomedicine, 11, 179-201. doi: 10.2147/ijn.s97286
Taurin, S., Nimick, M., Larsen, L., & Rosengren, R. J. (2016). A novel curcumin derivative increases the cytotoxicity of raloxifene in estrogen receptor-negative breast cancer cell lines. International Journal of Oncology, 48, 385-398. doi: 10.3892/ijo.2015.3252
Pritchard, T., Rosengren, R. J., Greish, K., & Taurin, S. (2016). Raloxifene nanomicelles reduce the growth of castrate-resistant prostate cancer. Journal of Drug Targeting, 24(5), 441-449. doi: 10.3109/1061186x.2015.1086360
Revalde, J. L., Li, Y., Hawkins, B. C., Rosengren, R. J., & Paxton, J. W. (2015). Heterocyclic cyclohexanone monocarbonyl analogues of curcumin can inhibit the activity of ATP-binding cassette transporters in cancer multidrug resistance. Biochemical Pharmacology, 93(3), 305-317. doi: 10.1016/j.bcp.2014.12.012
Taurin, S., Nehoff, H., van Aswegen, T., Rosengren, R. J., & Greish, K. (2014). A novel role for raloxifene nanomicelles in management of castrate resistant prostate cancer. BioMed Research International, 2014, 323594. doi: 10.1155/2014/323594
Taurin, S., Allen, K. M., Scandlyn, M. J., & Rosengren, R. J. (2013). Raloxifene reduces triple-negative breast cancer tumor growth and decreases EGFR expression. International Journal of Oncology, 43(3), 785-792. doi: 10.3892/ijo.2013.2012
Cridge, B. J., & Rosengren, R. J. (2013). Critical appraisal of the potential use of cannabinoids in cancer management. Cancer Management & Research, 5, 301-313. doi: 10.2147/CMAR.S36105
Journal - Research Other
Bland, A. R., Shrestha, N., Rosengren, R. J., & Ashton, J. C. (2020). Does crizotinib auto-inhibit CYP3A in vivo? [Brief report]. Pharmacology. Advance online publication. doi: 10.1159/000506996
Rana, Z., Diermeier, S., Hanif, M., & Rosengren, R. J. (2020). Understanding failure and improving treatment using HDAC inhibitors for prostate cancer. Biomedicines, 8(2), 22. doi: 10.3390/biomedicines8020022
Mortezaee, K., Salehi, E., Mirtavoos-mahyari, H., Motevaseli, E., Najafi, M., Farhood, B., Rosengren, R. J., & Sahebkar, A. (2019). Mechanisms of apoptosis modulation by curcumin: Implications for cancer therapy. Journal of Cellular Physiology, 234(8), 12537-12550. doi: 10.1002/jcp.28122
Salmaninejad, A., Valilou, S. F., Soltani, A., Ahmadi, S., Abarghan, Y. J., Rosengren, R. J., & Sahebkar, A. (2019). Tumor-associated macrophages: role in cancer development and therapeutic implications. Cellular Oncology, 42, 591-608. doi: 10.1007/s13402-019-00453-z
Keats, T., Rosengren, R. J., & Ashton, J. C. (2018). The rationale for repurposing sildenafil for lung cancer treatment. Anti-Cancer Agents in Medicinal Chemistry, 18(3), 367-374. doi: 10.2174/1871520617666171103100959
